Provenge (sipuleucel-T) / Bausch Health  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Provenge (sipuleucel-T) / Bausch Health
NCT01274572: Blood for Immune Response to Provenge® in HRPC

Withdrawn
N/A
0
US
Mary Crowley Medical Research Center
Prostate Cancer
01/11
06/11
NCT02042053: PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer

Terminated
N/A
10
US
PET/CT, PET/MRI
NYU Langone Health, Dendreon
Prostate Cancer
05/15
10/15
NCT02237170: Immune Monitoring on Sipuleucel-T

Completed
N/A
36
US
Icahn School of Medicine at Mount Sinai
Prostate Cancer
12/16
12/16
PROCEED, NCT01306890: A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Completed
N/A
1976
US
sipuleucel-T, PROVENGE, APC8015
Dendreon
Advanced Prostate Cancer, Prostatic Neoplasms
01/17
01/17
NCT01727154: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Terminated
N/A
139
US
Sipuleucel-T, PROVENGE, APC8015
Dendreon
Prostate Cancer
07/17
07/17
NCT02232230: A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Completed
N/A
20
US
Provenge
GenesisCare USA, Dendreon
Castrate Refractory Metastatic Prostate Cancer (mCRPC)
06/18
06/18
NCT01833208: Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Completed
N/A
15
US
Laboratory Biomarker Analysis, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
Roswell Park Cancer Institute, Dendreon
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
08/18
01/21
PEAX, NCT02353715: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

Completed
N/A
38
US
Enzalutamide, Xtandi, Abiraterone acetate, Zytiga, Sipuleucel-T, Provenge
Duke University
Prostate Cancer
11/18
11/18
NCT02456571: CTC Immune Checkpoint

Completed
N/A
38
US
CTC biomarker expression prevalence
Duke University, Janssen Research & Development, LLC
Prostate Cancer
06/19
06/19
NCT03329742: Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer

Completed
N/A
2
US
Low protein diet, Control protein diet
Indiana University, Indiana University School of Medicine
Prostate Cancer Recurrent
10/19
05/20

Download Options